HIV-Ⅰ慢病毒载体的研究进展与应用  

Progression and application of HIV-1-derived lentivectors

作　　者：蔡玉婵[1] 储以微[1] 

机构地区：[1]复旦大学上海医学院免疫学系(硕士研究生),上海200032

出　　处：《国际免疫学杂志》2008年第5期340-342,共3页International Journal of Immunology

基　　金：国家自然科学基金资助（30571713）

摘　　要：基因治疗是治疗肿瘤、遗传病等难治性疾病的最有效手段之一，但目前的基因转移方法存在一定的局限性，成为基因治疗和广泛应用的障碍。以1型人类免疫缺陷病毒（HIV-1）为基础构建的慢病毒载体（LV）具有感染分裂及非分裂细胞、使目的基因产物表达稳定、表达时间长、载体自身免疫原性小等优点，尤其是LV能有效诱导免疫应答，抑制肿瘤生长，诱导移植免疫耐受等，是很有发展潜力的体内基因治疗新载体。Gene therapy is one of the most effective methods to some refractory diseases such as cancer and hereditary diseases. However, the limits existing in transgenosis has become the biggest barrier for the extensive application of gene therapy. HIV-1 （ human immunodeficiency virus type 1 ） -based lentiviral vectors can transduce dividing or nondividing cells and can stably integrate into their targets for long-term expression. Accordingly, HIV-1-based lentiviral vectors are novel vectors with potential application in the induction of immune responses, inhibition of tumor growth and induction of the immue tolerance to allogrofts.

关 键 词：慢病毒载体 HIV-1 基因免疫治疗 

分 类 号：R[医药卫生]